Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Journal: Cancer discovery
Published: August 25, 2023
Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway.
Journal: Journal for immunotherapy of cancer
Published: March 01, 2022
AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.
Journal: Molecular cancer therapeutics
Published: December 10, 2014
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Journal: Molecular cancer therapeutics
Published: February 15, 2014
Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models.
Journal: Pharmacology research & perspectives
Published: June 27, 2013
Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition.
Journal: Bioorganic & medicinal chemistry letters
Published: February 16, 2012
Discovery of a new class of ghrelin receptor antagonists.
Journal: Bioorganic & medicinal chemistry letters
Published: November 21, 2011
Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2.
Journal: Bioorganic & medicinal chemistry letters
Published: October 03, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026